The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Small Molecule Inhibitors of CXCR4
Open accessAbstract
CXCR4 is a G-protein-coupled receptor involved in a number of physiological processes in the hematopoietic and immune systems. The SDF-1/CXCR4 axis is significantly associated with several diseases, such as HIV, cancer, WHIM syndrome, rheumatoid arthritis, pulmonary fibrosis and lupus. For example, CXCR4 is one of the major co-receptors for HIV entry into target cells, while in cancer it plays an important role in tumor cell metastasis. Several promising CXCR4 antagonists have been developed to block SDF-1/CXCR4 interactions that are currently under different stages of development. The first in class CXCR4 antagonist, plerixafor, was approved by the FDA in 2008 for the mobilization of hematopoietic stem cells and several other drugs are currently in clinical trials for cancer, HIV, and WHIM syndrome. While the long-term safety data for the first generation CXCR4 antagonists are not yet available, several new compounds are under preclinical development in an attempt to provide safer and more efficient treatment options for HIV and cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Crump, M. P., Gong, J., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana‐Seisdedos, F., Virelizier, J., Baggiolini, M., Sykes, B. D., & Clark‐Lewis, I. (1997) · The EMBO Journal · doi:10.1093/emboj/16.23.6996 · Cited by 731 · cited 2×
“Crump et al proposed a two-site theory for the binding of the natural ligand, SDF-1 with CXCR4 [12].”
BackgroundHernandez, P. A., Gorlin, R. J., Lukens, J. N., Taniuchi, S., Bohinjec, J., Francois, F., Klotman, M. E., & Diaz, G. A. (2003) · Nature Genetics · doi:10.1038/ng1149 · Cited by 722 · cited 2×
“Inherited mutations in the gene encoding CXCR4 have been also reported to correlate with the disorder [45, 46].”
Background
Cited by
Chloro-1,4-dimethyl-9H-carbazole Derivatives Displaying Anti-HIV Activity
Saturnino, C., Grande, F., Aquaro, S., Caruso, A., Iacopetta, D., Bonomo, M., Longo, P., Schols, D., & Sinicropi, M. (2018) · Molecules · doi:10.3390/molecules23020286 · Cited by 482
Self-citationCXCR4 over-expression and survival in cancer: A system review and meta-analysis
Zhao, H., Guo, L., Zhao, H., Zhao, J., Weng, H., & Zhao, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3217 · Cited by 274
The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond
Ullah, T. R. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100253 · Cited by 141
Jia, H., Ding, L., Yu, A., Tang, W., Tang, S., Zhang, C., & Oupický, D. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.07.018 · Cited by 12
Metadata
- Authors
- Debnath, B., Xu, S., Grande, F., Garofalo, A., & Neamati, N.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2013
- Volume
- 3
- Issue
- 1
- Pages
- 47-75
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2159812621
- Cited by
- 273
- References
- 3
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small Molecule Inhibitors of CXCR4. https://app.cochat.ai/papers/10.7150/thno.5376
- The paper
- Debnath, B., Xu, S., Grande, F., Garofalo, A., & Neamati, N. (2013). Small Molecule Inhibitors of CXCR4. Theranostics. https://doi.org/10.7150/thno.5376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
